The current classification scheme uses molecular alterations, particularly IDH1.R132H, to stratify lesions into distinct prognostic groups. Currently, neuroimaging followed by tissue biopsy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback